Horizon Therapeutics Public Limited Company

HZNP

IE00BQPVQZ61

Horizon Therapeutics Public : to buy Viela Bio for about $3.05 billion

February 01, 2021 at 12:12 pm

Feb 1 (Reuters) - Horizon Therapeutics said on Monday it will buy drug developer Viela Bio Inc for about $3.05 billion in an all-cash transaction. (Reporting by Trisha Roy in Bengaluru; Editing by Shinjini Ganguli)

Latest news about Horizon Therapeutics Public Limited Company

Health Canada Approves Horizon Therapeutics plc 's UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders	01-16	CI
Global markets live: Boeing, Amgen, Microsoft, Volkswagen, Tesla...	09/10/23
Horizon Therapeutics Public Limited Company Announces the Cessation of Member of the Board of Directors	06/10/23	CI
Amgen completes $27.8 bln Horizon deal	06/10/23	RE
Amgen Completes Acquisition of Horizon Therapeutics	06/10/23	MT
Amgen completes acquisition of Horizon Therapeutics	06/10/23	RE
Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from NASDAQ Composite Index	06/10/23	CI
Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from FTSE All-World Index	06/10/23	CI
Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Global BMI Index	06/10/23	CI
Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P TMI Index	06/10/23	CI
Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Biotechnology Select Industry Index	06/10/23	CI
Horizon Therapeutics Public Limited Company's Equity Buyback announced on September 9, 2022, has expired.	05/10/23	CI
Amgen Inc. completed the acquisition of Horizon Therapeutics Public Limited Company.	05/10/23	CI
Amgen Wins Irish Court Approval to Acquire Horizon Therapeutics	05/10/23	MT
Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from NASDAQ Biotechnology Index	05/10/23	CI
Horizon Therapeutics Public Limited Company Announces New Analysis of Adhering to Uninterrupted Full Course of Treatment with Tepezza to Support Thyroid Eye Disease Patient Outcomes	29/09/23	CI
EMEA Morning Briefing : Shares Seen Lower at Start of the Week	25/09/23	DJ
Nvidia, Amgen back AI-driven drug firm Generate:Biomedicines' $273 mln fundraise	14/09/23	RE
Horizon Therapeutics, Q32 Bio Say First Patient Dosed in Phase 2 Trial of Bempikibart in Severe Alopecia Areata	13/09/23	MT
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart for Severe Alopecia Areata	13/09/23	CI
FTC settlement could shelter Amgen from US price cuts, taxes	05/09/23	RE
Global markets live: Arm, Amgen, Lloyds, Novo Nordisk, Nestlé...	04/09/23
News Highlights : Top Company News of the Day	04/09/23	DJ
Health Care Up as Traders Hedge on Growth Views -- Health Care Roundup	01/09/23	DJ
Sector Update: Health Care Stocks Rising in Late Afternoon Trading	01/09/23	MT

Chart Horizon Therapeutics Public Limited Company

Duration

Period

Chart Horizon Therapeutics Public Limited Company

More charts

Company Profile

Horizon Therapeutics plc is an Ireland-based global biotechnology company. The Company is focused on the discovery, development and commercialization of medicines that address the critical needs of people impacted by rare, autoimmune and severe inflammatory diseases. The Companyâs portfolio of medicines include ACTIMMUNE, BUPHENYL (sodium phenylbutyrate), PROCYSBI (cysteamine bitartrate), Prescription RAVICTI (glycerol phenylbutyrate), and other. ACTIMMUNE is part of a drug regimen used to treat Chronic Granulomatous Disease (CGD). BUPHENYL (sodium phenylbutyrate) is a tablet for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contains sodium phenylbutyrate. PROCYSBI (cysteamine bitartrate) delayed-release capsules and delayed-release oral granules is a prescription medicine used to treat nephropathic cystinosis in adults and children 1 year of age and older.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
NOVARTIS AG	+9.78%	210B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B

Other Pharmaceuticals